하이알루론산 시장 크기 및 공유 2025 – 2034

Hyaluronic Acid Market Size

The global hyaluronic acid market size was valued at USD 5.4 billion in 2024. The market is anticipated to grow from USD 5.9 billion in 2025 to USD 11 billion in 2034, growing at a CAGR of 7.1% from 2025 to 2034. High market growth is primarily attributed to technological advancements in HA-based products, increasing prevalence of osteoarthritis and rise in number of aesthetic procedures among other factors.
 

Interest in cosmetic procedures, especially by younger individuals, is witnessing faster growth, driven by increased awareness of appearance, regular social media presence, and the desire to look younger. For instance, as per the data reported by ISAPS, around 34.9 million total aesthetic procedures were performed globally including surgical and non-surgical in 2023. Hyaluronic acid is a central component in many dermal fillers as it is used in lip enhancement, improves skin moisture levels among other applications. Countries such as the U.S., South Korea, and Brazil are witnessing a continual demand for HA fillers with millennials and middle-aged consumers leading the trend.
 

Increase in the elderly population is pushing up osteoarthritis rates globally, especially in knee and hip joints. Healthcare professionals now inject hyaluronic acid directly into these stiff joints in a treatment called viscosupplementation, aiming to restore natural lubrication and ease pain. Because many patients prefer a non-surgical option over full joint replacement, orders for HA injections are expected to record significant surge over the forecast timeframe.
 

Hyaluronic acid occurs naturally in connective tissues, skin, and synovial fluid that cushions joints. Its main job is to lubricate, hydrate, and absorb shock in both cartilage and external applications like skincare or wound gels.
 

Hyaluronic Acid Market Trends

• Rising demand for non-animal, bio-fermented hyaluronic acid, shift toward single-injection viscosupplementation therapies coupled with rise in preventive anti-aging treatments are among the key market trends fueling the industry growth.
   
• Both consumers and health-care professionals are increasingly choosing non-avian hyaluronic acid made through bacterial fermentation. This trend stems from safety related issues, religious and ethical values and offers improved product consistency. The approach allows brands to market themselves as vegan and cruelty-free in both cosmetic and therapeutic lines.
   
• Additionally, the industry is moving toward single-injection hyaluronic acid products for osteoarthritis. These options are cutting down on extra clinic trips, offering quick ease of use, and thus lifting patient follow-throughs. Products by leading companies such as DUROLANE from Bioventus and MONOVISC by Anika Therapeutics are playing a key role in this trend.
   
• Furthermore, the rise of preventive aesthetics among younger users, impacted by social media, is encouraging earlier and broader use of HA-based cosmetic treatments. Hence, the aforementioned pointers are expected to play a key role in pushing market growth into an upward trajectory.
   

Hyaluronic Acid Market Analysis

In 2021, the global market was valued at USD 4 billion. The following year, it saw a slight increase to USD 4.4 billion, and by 2023, the market further climbed to USD 4.9 billion. Based on product, the global market is segmented into multiple injection dose and single injection dose. The multiple injection dose segment accounted for the leading market share and was valued at USD 3.1 billion in 2024.
 

• Both patients and healthcare professionals continue to ask for multiple-injection HA doses for osteoarthritis treatment as this is a proven method. Such protocols usually call for three to five weekly shots and suit those with moderate to severe joint wear and expect steady relief.
   
• Such multi-dose products have a well-established clinical track record, receive regular insurance reimbursement, and are backed by extensive research showing they enhance joint lubrication and diminish discomfort over time.
   
• Though single-injection formulas gain traction for their convenience, some orthopedic surgeons continue to prefer the multi-dose approach because it delivers HA in a more controlled manner and builds benefits over time. For instance, in countries such as Japan and several European nations, these multiple doses still represent the standard of care.
   
• Further, cost-sensitive healthcare systems may also favor the multi-injection regimen since the price per syringe is lower than that of premium single-dose brands, making overall treatment more affordable.
   

Based on application, the global hyaluronic acid market is categorized into osteoarthritis, dermal fillers, ophthalmic, vesicoureteral reflux, and other applications. The osteoarthritis segment accounted for leading share in the market in 2024 and is expected to reach around USD 4.9 billion in 2034.
 

• Demand for hyaluronic acid to treat osteoarthritis keeps rising as more people worldwide, especially older adults, develop pain in knees and hips. HA works as a viscosupplement, clinicians inject it directly into the joint so thicker synovial fluid eases friction and discomfort.
   
• When over-the-counter pills or non-steroidal anti-inflammatories offer little relief, many patients seek HA shots because they are quick, drug-free, and less invasive. The growing inclination to postpone surgery or avoid full joint replacement further adds to the trend.
   
• Additionally, hyaluronic therapy is also popular because it results in fewer systemic side effects, an important consideration for elderly patients who are on multiple medications.
   
• Moreover, in the U.S., favorable insurance coverage paired with FDA-cleared brands such as Synvisc-One and Durolane propels the market growth, while some of the Asian and European countries are also expanding their use through public arthritis programs and increased referrals from orthopedic specialists.
   

Based on grade, the global hyaluronic acid market is segmented into pharmaceutical grade hyaluronic acid and cosmetic grade hyaluronic acid. The pharmaceutical grade hyaluronic acid segment accounted for the leading market share and was valued at around USD 3.7 billion in 2024.
 

• The demand for pharmaceutical-grade hyaluronic acid (HA) is witnessing substantial rise as it is being used in range of applications including viscosupplementation in orthopedics, eye surgery to drug-delivery systems. This pharmaceutical-grade HA comes with high purity, well-controlled molecular weight, and tighter biocompatibility regulations, that enables it for injectable or implanted use.
   
• In orthopedics, clinicians inject it directly into joints to relieve osteoarthritis pain, while ophthalmologists use it as a viscoelastic cushion during cataract and retinal procedures.
   
• The growing preference for fermentation-derived HA is also rising because this source poses less risk of immune reaction and delivers steady quality. Favorable support from regulatory authorities such as FDA further improves the material's credibility across healthcare facilities.
   
• Furthermore, research teams are exploring combinations of hyaluronic acid with regenerative medicines, hence expected to open exciting new drug possibilities.
   

Based on source of origin, the global hyaluronic acid market is categorized into non-avian origin and avian origin. The non-avian origin segment accounted for leading share in the market in 2024 and is expected to reach around USD 9.1 billion in 2034.
 

• In the pharmaceutical and cosmetics markets, the demand for hyaluronic acid manufactured without animal sources is rising considerably as it is safer, easier to scale, and has better ethical standing. It is produced by fermenting bacteria, usually Streptococcus zooepidemicus, and yields a more consistent product. It also carries a much lower risk of allergies and other safety problems.
   
• In healthcare it has become the first choice for viscosupplements, eye surgeries, and urological procedures, especially where regulators insist on full traceability and minimal contamination.
   
• In addition, cosmetic procedures also favor non-avian HA because it fits the vegan, cruelty-free, and halal trends that attract socially aware shoppers.
   
• Further, manufacturers prefer the scalable and controllable fermentation process that delivers steady supply and uniform quality. Manufacturing facilities of leading players especially in developed regions, are driving this shift, contributing to market growth.
   

Based on end use, the global hyaluronic acid market is classified into hospitals, dermatology clinics, ambulatory surgical centers, and other end users. In 2024, the hospitals segment held highest market share and is expected to showcase significant growth over the analysis period.
 

• Hospitals are a major driving force behind hyaluronic acid demand globally, especially within orthopedic, eye-care, and aesthetic surgery sections. In these departments HA is used in viscosupplementation, cataract surgery, that requires high-purity, pharmaceutical-grade supplies.
   
• The presence of skilled practitioners, supportive reimbursement policies, and clear regulatory pathways further cement HA-based treatments as standard practice.
   
• As institutions lean more toward minimally invasive techniques, the need for hyaluronic acid grows notably for inpatient arthritis management and eye procedures that call for viscoelastic agents.
   

The North America hyaluronic acid market accounted for leading share and was valued at USD 2.3 billion in 2024. Favorable reimbursement policies, coupled with rise in awareness levels and increasing prevalence of osteoarthritis are expected to drive regional growth.
 

The U.S. market was valued at USD 1.6 billion and USD 1.7 billion in 2021 and 2022, respectively. The market size reached USD 2.1 billion in 2024, growing from USD 1.9 billion in 2023.
 

• The U.S. stands as one of the world’s largest markets as people widely receive dermal fillers, there is a high prevalence of osteoarthritis in the country for insurance plans are available and they reimburse several viscosupplement injections.
   
• Cosmetic treatments featuring HA remain especially popular among older adults as well as younger individuals looking for quick and fermented sources of HA-based treatments.
   
• In addition, the country’s stringent regulatory environment, with most products carrying FDA approval, and its extensive healthcare network make HA services routine in both hospitals and private clinics.
   
• Further, demand for single-injection brands such as Synvisc One and Durolane, coupled with the demand for bio-fermented, non-animal HA, keeps pushing product growth in both medical and beauty sectors.
   

Europe hyaluronic acid market accounted for significant revenue share and was valued at around USD 1.6 billion in 2024 and is anticipated to show lucrative growth over the forecast period.
 

• In Europe, a high level of public awareness, an aging population, and the willingness to try newer orthopedic and aesthetic procedures have pushed the market growth upward. National health plans in Italy, France, and Spain, among other countries provide reimbursement for some of the viscosupplementation procedures for knee arthritis, thus driving sales.
   
• Europe is among the world’s largest users of dermal fillers and HA-infused skin products, as consumers seek effective anti-aging solutions.
   
• Strict regulation now favors HA made without animal-derived material, boosting safety and batch consistency and product uniformity. In addition, many European consumers prioritize ethics, so cruelty-free and vegan formulations are gaining market share in both therapy and cosmetics.
   

The Germany hyaluronic acid market is expected to witness considerable growth over the analysis period.
 

• Germany exhibits robust demand for hyaluronic acid, especially in clinical-grade applications found in orthopedics and ophthalmology. Healthcare facilities in the country combined with high level of per capita healthcare spending, facilitate the frequent adoption of HA-based therapies especially in joint-related treatments.
   
• Germany is also Europe's leading market for aesthetic medicine, which is witnessing a consistent rise in number of private clinics that provide HA-based dermal fillers to patients.
   
• Moreover, both German manufacturers and end-users prefers premium, EU-compliant, non-animal HA, prioritizing biocompatibility, clear traceability, and rigorous clinical evidence when selecting suppliers. In public and private hospitals, adherence to regulations and guidance from physicians remain decisive factors shaping the uptake of new products.
   

The Asia Pacific hyaluronic acid market is anticipated to grow at the highest CAGR of 8.1% during the analysis timeframe.
 

• The market in the Asia-Pacific region is growing rapidly, fueled by booming medical tourism, greater interest in aesthetic procedures, and a rising number of osteoarthritis cases among older adults. Countries such as South Korea and Japan are among the leading users of dermal fillers in the region as their beauty-oriented societies and cutting-edge cosmetic industries keep the demand high.
   
• Additionally, China and India show strong need for HA in orthopedic and eye-care products as better health infrastructure and a growing middle class increase purchasing power. A well-developed local manufacturing network that produces non-avian HA also supports exports and steady domestic supply.
   
• Furthermore, broad cultural preference for non-invasive therapy, coupled with reduction in treatment costs, is playing a key role in overall market expansion.
   

China hyaluronic acid market is predicted to grow significantly over the forecast period.
 

• China is rapidly emerging as the world’s largest market, with cosmetic procedures including injectable dermal fillers contributing to increased popularity among urban women and younger individuals looking for quick facial refreshers.
   
• A healthy rise in knee osteoarthritis cases, paired with expanded public-health coverage, is pushing up demand for HA in therapeutic joints.
   
• Moreover, supportive government policies for biotech and med-tech research is further fueling the homegrown innovation to craft novel combination therapies built around hyaluronic acid-based formulations.
   

Brazil is experiencing significant growth in the Latin America hyaluronic acid market and is anticipated to record robust growth throughout the forecast period.
 

• In Brazil, the majority of hyaluronic acid sales comes from cosmetic procedures as dermal fillers appeal to many younger men and women since it allows the user to have an appealing look.
   
• Growing demand for faster, minimally invasive procedures is surging in metro cities such as Sao Paulo and Rio de Janeiro, thus pushing up the orders for HA injectables.
   
• Further, rising cases of osteoarthritis and sport injuries promotes viscosupplementation use. However, since majority of the country's HA supply is imported, consumers increasingly prefer non-avian, bio-fermented grades that meet safety and ethical guidelines.
   

Saudi Arabia hyaluronic acid market is poised to witness substantial growth in Middle East and Africa market during the forecast period.
 

• Demand for hyaluronic acid in Saudi Arabia is witnessing substantial growth owing to rise in healthcare spending, an uptick in lifestyle ailments such as osteoarthritis, and a booming aesthetics sector push the product usage upward. Under the Vision 2030 plan, the government is also broadening access to advanced treatments, from HA-based joint injections to other ophthalmic procedures.
   
• In addition, cultural shifts and higher disposable income are encouraging more people especially women to seek dermal fillers and other anti-aging services. Consumers in the country request halal-compliant, non-avian sources, so imports of bio-fermented HA in the country are rising sharply.
   
• Furthermore, coupled with ongoing infrastructure upgradation and increased health awareness, Saudi Arabia is emerging as a fast-growing market for both therapeutic and cosmetic hyaluronic acid applications.
   

Hyaluronic Acid Market Share

Companies operating in the hyaluronic acid industry are actively involved in expanding their product lineup of injectable products while refining efficacy and boosting patient ease with smarter formulas. Leading industry players such as Anika Therapeutics, Allergan Aesthetics, BLOOMAGE, FERRING PHARMACEUTICALS and Bioventus are investing into next-gen single-injection options that reduced the treatment load.
 

Top 5 players contributed more than 40% of market share. They have a keen focus towards non-avian HA made by bacterial fermentation, a shift that promises cleaner, safer material and wider patient acceptance. Additionally, meeting regulations, gathering real-world data, and actively informing clinicians remain vital to staying ahead in orthopedics and aesthetics.
 

Hyaluronic Acid Market Companies

Few of the prominent players operating in the hyaluronic acid industry include:

• Allergan Aesthetics
• altergon
• ANIKA
• bioventus
• BLOOMAGE
• FERRING PHARMACEUTICALS
• GALDERMA
• kewpie
• LG Chem
• Lifecore BIOMEDICAL
• Roche
• Sanofi
• SEIKAGAKU CORPORATION
• Teleflex (Deflux)
• TOPSCIENCE
   
• ANIKA specializes in non-avian origin hyaluronic acid-based injectables, offering a broad viscosupplementation portfolio with both single and multi-injection options, supported by strong research and development in regenerative joint preservation.
   
• Bioventus leverages a robust orthopedic network and offers well-known HA-based products such as DUROLANE, focusing on single-injection convenience and clinical evidence to support pain relief in osteoarthritis patients.
   

Hyaluronic Acid Industry News

• In June 2023, Galderma announced that it has received FDA approval for its latest hyaluronic acid filler Restylane Eyelight in the U.S. The product is formulated with NASHA technology and may enable the company to gain more ground in the U.S. market in the coming years.
   
• In May 2023, Allergan Aesthetics, an AbbVie company, announced that it has received FDA approval for its SKINVIVE injection by JUVÉDERM in the U.S. SKINVIVE is among the first hyaluronic acid (HA) based intradermal microdroplet injection for skin smoothness which is available in the country. This development highlights the company's strategy and focus on innovation to remain in a leading position in comparison to its peers.
   

The hyaluronic acid market research report includes in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2021 - 2034 for the following segments:

Market, By Product

• Multiple injection dose
• Single injection dose

Market, By Application

• Osteoarthritis
• Dermal fillers
• Ophthalmic
• Vesicoureteral reflux
• Other applications

Market, By Grade

• Pharmaceutical grade hyaluronic acid
• Cosmetic grade hyaluronic acid

Market, By Source of Origin

• Non-avian origin
• Avian origin

Market, By End Use

• Hospitals
• Ambulatory surgical centers
• Orthopedic clinics
• Other end use

The above information is provided for the following regions and countries: